EBMT 2023 | Optimizing the treatment of transplant-eligible NDMM: using quadruplets in induction & consolidation
Elias Mai, MD, University Hospital Heidelberg, Heidelberg, Germany, comments on the benefit of autologous transplantation and quadruplets in the induction and consolidation of patients with transplant-eligible newly diagnosed multiple myeloma (NDMM), also highlighting the possibility of adding an anti-CD38 antibody to maintenance therapy to optimize the outcomes of these patients. This interview took place at the 49th Annual Meeting of the European Group for Blood and Marrow Transplantation (EBMT) held in Paris, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Consulting or Advisory Role, Honoraria, Research Funding, and Travel Accommodations and Expenses – Bristol Myers Squibb/Celgene, GlaxoSmithKline, Janssen-Cilag, Sanofi, Stemline and Takeda.
